Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension.

Abstract

BACKGROUND:

Orthostatic hypotension causes ≈80 000 hospitalizations per year in the United States. Treatments for orthostatic hypotension include fludrocortisone, a mineralocorticoid analog that promotes sodium reabsorption; and midodrine, an α-1 adrenergic agonist that is a direct vasoconstrictor. Although both medications are used to treat orthostatic hypotension, few studies have compared their relative safety.

METHODS AND RESULTS:

We compared incidence rates of hospitalizations for all causes, and for congestive heart failure between users of fludrocortisone and users of midodrine in a retrospective cohort study of Tennessee Medicaid adult enrollees (1995-2009). Adjusted incidence rate ratios were calculated using negative binomial regression models. Subgroup analyses based on history of congestive heart failure were conducted. We studied 1324 patients initiating fludrocortisone and 797 patients initiating midodrine. Compared with fludrocortisone users, midodrine users had higher prevalence of cardiovascular conditions. Incidence rates of all-cause hospitalizations for fludrocortisone and midodrine users were 1489 and 1330 per 1000 person-years, respectively (adjusted incidence-rate ratio 1.20, 95% confidence interval, 1.02-1.40). The respective rates of heart failure-related hospitalization were 76 and 84 per 1000 person-years (adjusted incidence-rate ratio: 1.33, 95% confidence interval, 0.79-2.56). Among patients with a history of congestive heart failure, the rates of all-cause hospitalization for fludrocortisone and midodrine were 2448 and 1820 per 1000 person-years (adjusted incidence-rate ratio: 1.42, 95% confidence interval, 1.07-1.90), and the respective rates of heart failure exacerbation-related hospitalizations were 297 and 263 per 1000 person-years (adjusted incidence-rate ratio: 1.48, 95% confidence interval, 0.69-3.16).

CONCLUSIONS:

Compared with users of midodrine, users of fludrocortisone had higher rates of all-cause hospitalizations, especially among patients with congestive heart failure.

• Authors: Carlos G Grijalva, Italo Biaggioni, Marie R Griffin, Cyndya A Shibao
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 6 Issue 10 (Oct 12 2017) ISSN: 2047-9980 [Electronic] England
• PMID: 29025750 (Publication Type: Comparative Study, Journal Article)
• Copyright: © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Chemical References

• Adrenergic alpha-1 Receptor Agonists
• Vasoconstrictor Agents
• Midodrine
• Fludrocortisone

Topics

• Adrenergic alpha-1 Receptor Agonists (adverse effects)
• Aged
• Blood Pressure (drug effects)
• Databases, Factual
• Female
• Fludrocortisone (adverse effects)
• Heart Failure (diagnosis, epidemiology, physiopathology, therapy)
• Hospitalization
• Humans
• Hypotension, Orthostatic (diagnosis, drug therapy, epidemiology, physiopathology)
• Incidence
• Logistic Models
• Male
• Medicaid
• Middle Aged
• Midodrine (adverse effects)
• Multivariate Analysis
• Prevalence
• Propensity Score
• Retrospective Studies
• Risk Factors
• Tennessee (epidemiology)
• Time Factors
• Treatment Outcome
• United States
• Vasoconstrictor Agents (adverse effects)